drugset / Trial / NCT03217565

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

NCT03217565

Phase 1 Completed 47 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to pediatric participants, full-term neonates, and preterm neonates.

Timeline

Start
2019-02-06
Primary completion
2023-03-18
Completion
2023-04-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tedizolid Phosphate Small molecule 2.5 mg/kg Intravenous
Subject Tedizolid Phosphate Small molecule 3 mg/kg Intravenous